ClinicalTrials.gg

Program

Anti-CD70 CAR-expressing T Lymphocytes

Also written as “CD70 CAR-T cells” and “BCMA/CD70 CAR-T cells”.

Its studies are mostly in Neoplasm Metastasis · Lupus Erythematosus, Systemic · Ovarian Neoplasms · Carcinoma, Renal Cell, led by Chongqing Precision Biotech.

Furthest: phase 1, since Jun 12, 20226 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Precision Biotech66 open or runningphase 1since Jun 12, 2022Jun 12, 2022Dec 31, 2026phase 1 · NCT06215950

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2022First studies: 2 phase 1 studies in Neoplasm MetastasisFirst studyNCT05420545, NCT05420519
  2. Jul 19, 2022Phase 1 study in Neoplasm MetastasisNCT05468190 · 48 planned · China
  3. Aug 18, 2023Phase 1 study in Carcinoma, Renal CellNCT06010875 · 48 planned · China
  4. Jan 11, 2024Phase 1 study in Ovarian NeoplasmsNCT06215950 · 36 planned · China
  5. Dec 11, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07318259 · 18 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Ovarian NeoplasmsNCT06215950

TargetBeta

CD70 →read by rule
“A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member ”NCIt, by rule

Other programs on CD70

ProgramCompanyFurthest phaseStudies
Anti-CD70/CD3 Bispecific Antibody INCA036873ruleIncytephase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07318259Lupus Erythematosus, Systemic · China1RecruitingJul 202618
NCT06215950Ovarian Neoplasms · China1RecruitingDec 31, 202636
NCT06010875Carcinoma, Renal Cell · China1RecruitingDec 31, 202548
NCT05468190Neoplasm Metastasis · China1RecruitingJul 17, 202448
NCT05420545Neoplasm Metastasis · China1RecruitingDec 31, 202336
NCT05420519Neoplasm Metastasis · China1RecruitingDec 31, 202324

How it is read

Names in the registry

  • “CD70 CAR-T cells”, 9 entries
  • “BCMA/CD70 CAR-T cells”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.